AZ191
Cat. No.:YN440199
产品名称: | AZ191 |
CAS No.: | 1594092-37-1 |
Chemical Name: | N-[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-pyrimidinamine |
Synonyms: | AZ 191;[2-Methoxy-4-(4-methyl-piperazin-1-yl)-phenyl]-[4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-pyrimidin-2-yl]-amine;2-Pyrimidinamine, N-[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-;AZ-19 |
分子量: | 429.52 |
分子式: | C₂₄H₂₇N₇O |
SMILES: | CN1C2=CN=CC=C2C(C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4OC)=NC=C3)=C1 |
存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
运输: | Room temperature in continental US; may vary elsewhere. |
产品描述: | AZ191 是DYRK1B高效选择性抑制剂,IC50值 17 nM。 |
IC50和靶点: | |
In Vitro: | |
In Vivo: | |
Clinical Trial: | |
Solvent & Solubility: |
Becker, W.Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle controlCell Cycle11(18),3389-3394(2012)
Gao, J., Zheng, Z., Rawal, B., et al.Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cellsCancer Biol. Ther.8(17),1671-1679(2009)
Keramati, A.R., Fathzadeh, M., Go, G.W., et al.A form of the metabolic syndrome associated with mutations in DYRK1BN. Engl. J. Med.370(20),1909-1919(2014)
Ashford, A.L., Oxley, D., Kettle, J., et al.A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288)Biochem. J.457(1),43-56(2014)